Table 2 Type and quality of cancer services for the “before” and “after” periods, in the reference centre and in the two peripheral centres
| Â | Overall | Â | Reference centre | Â | Peripheral centres | Â | |||
|---|---|---|---|---|---|---|---|---|---|
| Â | Before | After | p | Before | After | p | Before | After | p |
Description | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Surgery | Â | Â | 1.00 | Â | Â | 1.00 | Â | Â | 0.96 |
Yes | 305 (99.7) | 360 (99.7) | Â | 149 (100.0) | 193 (100.0) | Â | 156 (99.4) | 167 (99.4) | Â |
No | 1 (0.3) | 1 (0.3) | Â | 0 (0.0) | 0 (0.0) | Â | 1 (0.6) | 1 (0.6) | Â |
Chemotherapy | Â | Â | 0.07 | Â | Â | 0.45 | Â | Â | 0.04 |
Yes | 151 (49.3) | 152 (42.2) | Â | 79 (53.0) | 94 (48.7) | Â | 72 (45.9) | 58 (34.7) | Â |
No | 155 (50.7) | 208 (57.8) | Â | 70 (46.9) | 99 (51.3) | Â | 85 (54.1) | 109 (65.3) | Â |
Exposition to taxane | Â | Â | <0.0001 | Â | Â | <0.0001 | Â | Â | <0.0001 |
Yes | 90 (59.6) | 149 (98.0) | Â | 51 (64.6) | 93 (98.9) | Â | 39 (54.2) | 56 (96.6) | Â |
No | 61 (40.4) | 3 (2.0) | Â | 28 (35.4) | 1 (1.1) | Â | 33 (45.8) | 2 (3.4) | Â |
Hormone therapy | Â | Â | 0.84 | Â | Â | 0.51 | Â | Â | 0.63 |
Yes | 251 (82.3) | 293 (81.4) | Â | 118 (79.7) | 148 (76.7) | Â | 133 (84.7) | 145 (86.8) | Â |
No | 54 (17.7) | 67 (18.6) | Â | 30 (20.3) | 45 (23.3) | Â | 24 (15.3) | 22 (13.2) | Â |
Radiotherapy | Â | Â | 0.59 | Â | Â | 0.84 | Â | Â | 0.35 |
Yes | 281 (91.8) | 327 (90.6) | Â | 136 (91.3) | 178 (92.2) | Â | 145 (92.4) | 149 (88.7) | Â |
No | 25 (8.2) | 34 (9.4) | Â | 13 (8.7) | 15 (7.8) | Â | 12 (7.6) | 19 (11.3) | Â |
Delayed treatment (>12 weeks) | Â | Â | 0.81 | Â | Â | 0.85 | Â | Â | 0.93 |
No | 302 (98.7) | 357 (98.9) | Â | 148 (99.3) | 192 (99.5) | Â | 154 (98.1) | 165 (98.2) | Â |
Yes | 4 (1.3) | 4 (1.1) | Â | 1 (0.7) | 1 (0.5) | Â | 3 (1.9) | 3 (1.8) | Â |
Time between surgery and adjuvant chemotherapy (weeks) | 6.0 ± 3.0 | 5.6 ± 3.6 | 0.11 | 5.1 ± 2.2 | 5.3 ± 3.7 | 0.87 | 6.7 ± 3.4 | 6.0 ± 3.4 | 0.17 |
4.9 [1.0-20.4] | 4.9 [0.3-31.7] | Â | 4.6 [1.6-15.4] | 4.6 [0.3-31.7] | Â | 6.6 [1.0-20.4] | 5.3 [1.1-17.1] | Â | |
Dose-dense | Â | Â | 0.22 | Â | Â | 0.60 | Â | Â | 0.32 |
Yes | 126 (86.3) | 113 (91.1) | Â | 70 (90.9) | 69 (93.2) | Â | 56 (81.2) | 44 (88.0) | Â |
No | 20 (13.7) | 11 (8.9) | Â | 7 (9.1) | 5 (6.8) | Â | 13 (18.8) | 6 (12.0) | Â |
24-month progression free survival (%) | 96.8 | 95.6 | 0.79 | 95.2 | 96.7 | 0.68 | 96.6 | 94.0 | 0.93 |